Immunotoxicity of a standardized citrus polymethoxylated flavone extract

被引:47
作者
Delaney, B
Phillips, K
Buswell, D
Mowry, B
Nickels, D
Cox, D
Wang, HB
Manthey, J
机构
[1] Cargill Nutraceut, Minneapolis, MN 55440 USA
[2] Midwest Res Inst, Kansas City, MO 64110 USA
[3] Cargill Feed Applicat, Minneapolis, MN 55440 USA
[4] Cargill CitroAmer Inc, Frostproof, FL 33843 USA
[5] ARS, USDA, SAA, US Citrus & Subtrop Prod Lab, Winter Haven, FL 33881 USA
关键词
citrus; flavones; immunotoxicity; natural killer cells (NK cells);
D O I
10.1016/S0278-6915(01)00058-8
中图分类号
TS2 [食品工业];
学科分类号
0832 [食品科学与工程];
摘要
Polymethoxylated flavones (PMFs) from citrus inhibit production of TNF-alpha and other pro-inflammatory cytokines. As TNF-alpha also modulates NK cell activity, the current studies were conducted to assess the potential for a standardized citrus PMF mixture to suppress humoral and innate immune functions. PMFs were isolated from orange peel oil using a procedure that obtained a consistent mixture of PMFs both in identity and proportion. The mixture consisted of nobiletin (30.7%), 3,3 ' ,4,5,6,7,8-heptamethoxyflavone (27.9%), trimethylscutellarein (14.5%), tangeretin (10.4%), sinensetin (5.8%), 5-demethyl-nobiletin (2.0%), hexa-O-methylquercetagetin (1.3%), 5-demethyl-tetramethylscutellarein (0.6%), and other flavonoids (2.7%). To assess the effect of the PMF mixture on humoral immune responses, female B6C3F1 mice (n = 8) were exposed to the PMF by gavage at 5, 50, 150 and 500 mg/kg/day for 28 days. On day 25, mice were sensitized to sRBC by tail vein injection and AFC response determined 4 days later. Humoral immunity was insensitive to suppression following exposure to all concentrations of the PMF mixture. Suppression of NK cell activity was observed only following 500 mg/kg/day for 28 days. Body weights were not affected by exposure to any concentration of the PMF mixture in sRBC immunized or non-immunized mice. However, in sRBC-immunized mice, higher concentrations of PMF were associated with a statistically insignificant increase in spleen weight (P > 0.05). No change in spleen weight was observed in non-immunized mice. As anticipated, based on previously published in vitro observations, long-term, high-dose exposure to a standardized mixture of citrus PMFs caused a mild suppression of NK cell activity; however, humoral immunity was not sensitive to suppression at the same exposure levels. (C) 2001 Published by Elsevier Science Ltd.
引用
收藏
页码:1087 / 1094
页数:8
相关论文
共 39 条
[1]
Differential effect of flavonoids on inhibition of secretion and accumulation of secretory granules in rat basophilic leukemia cells [J].
Alexandrakis, M ;
Singh, L ;
Boucher, W ;
Letourneau, R ;
Theofilopoulos, P ;
Theoharides, TC .
INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 1999, 21 (06) :379-390
[2]
GENISTEIN, A SELECTIVE PROTEIN TYROSINE KINASE INHIBITOR, INHIBITS INTERLEUKIN-2 AND LEUKOTRIENE-B4 PRODUCTION FROM HUMAN MONONUCLEAR-CELLS [J].
ATLURU, D ;
JACKSON, TM ;
ATLURU, S .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1991, 59 (03) :379-387
[3]
BARTSCH W, 1976, ARZNEIMITTEL-FORSCH, V26, P1581
[4]
Effects of oral administration of purified micronized flavonoid fraction on increased microvascular permeability induced by various agents and on ischemia/reperfusion in the hamster cheek pouch [J].
Bouskela, E ;
Donyo, KA .
ANGIOLOGY, 1997, 48 (05) :391-399
[5]
Influence of tangeretin on tamoxifen's therapeutic benefit in mammary cancer [J].
Bracke, ME ;
Depypere, HT ;
Boterberg, T ;
Van Marck, VL ;
Vennekens, KM ;
Vanluchene, E ;
Nuytinck, M ;
Serreyn, R ;
Mareel, MM .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (04) :354-359
[6]
TNFα and MIP-2:: role in particle-induced inflammation and regulation by oxidative stress [J].
Driscoll, KE .
TOXICOLOGY LETTERS, 2000, 112 :177-183
[7]
ORAL ADMINISTRATION OF PURIFIED MICRONIZED FLAVONOID FRACTION SUPPRESSES LEUKOCYTE ADHESION IN ISCHEMIA-REPERFUSION INJURY - IN-VIVO OBSERVATIONS IN THE HAMSTER SKIN FOLD [J].
FRIESENECKER, B ;
TSAI, AG ;
ALLEGRA, C ;
INTAGLIETTA, M .
INTERNATIONAL JOURNAL OF MICROCIRCULATION-CLINICAL AND EXPERIMENTAL, 1994, 14 (1-2) :50-55
[8]
GILMAN SC, 1988, PHARM LYMPHOCYTES, P345
[9]
Goda Y, 1999, BIOL PHARM BULL, V22, P1319, DOI 10.1248/bpb.22.1319
[10]
HOLSAPPLE MP, 1995, METHODS IMMUNOTOXICO, V1, P71